ONVECTION-enhanced delivery is increasingly used to distribute therapeutic agents to the CNS to treat a variety of disorders. In CED, a small hydrostatic pressure differential imposed by a syringe pump to distribute infusate directly to small or large regions of the CNS is used in a safe, reliable, targeted, and homogeneous manner that bypasses the blood-nervous system barrier. Convection-enhanced delivery has a number of advantages over existing delivery techniques and has permitted the development of a number of new treatment approaches in preclinical and clinical studies. [7] [8] [9] 11 Nevertheless, the optimal use of convective distribution of a therapeutic infusate requires the development of imaging tracers to monitor drug distribution during CED.
ning, QAR, serial clinical observations, and histopathological analyses.
Materials and Methods

Tracer Use for CT Scanning
Iopamidol (MW 777 D, concentration 408 mg/ml; Isovue-M200; Bracco Diagnostics, Princeton, NJ), containing 20% organically bound iodine (200 mg/ml; pH 6.5-7.5) was the imaging tracer used for distribution in this study.
Toxicity Trial of Iopamidol in Rats
All animal investigations were conducted in accordance with the National Institutes of Health guidelines on the use of animals in research and were approved by the Animal Care and Use Committee of the National Institute of Neurological Disorders and Stroke.
Six adult male Sprague-Dawley rats (each weighing between 300 and 400 g) were anesthetized by intraperitoneal administration of 80 mg/kg ketamine and 10 mg/kg xylazine, and placed in a stereotactic frame (Kopf Instruments, Tujunga, CA). A midsagittal scalp incision was made to the level of the skull and a burr hole was placed over the right frontal region. A 32-gauge cannula attached to a 25-l Hamilton syringe (Thompson Scientific Instruments, Clear Brook, VA) filled with iopamidol was stereotactically placed in the right striatum. The coordinates for placement of the cannula tip in the striatum were 0.5 mm anterior to the bregma, 2.8 mm right of midline, and 5 mm below the dura mater.
To distribute the infusate (iopamidol) by convection, we used a noncompliant, gas-tight infusion apparatus consisting of a syringe pump (Harvard Apparatus, South Natick, MA) that generates a continuous pressure gradient, which is transmitted through a hydraulic drive attached to the infusate syringe plunger. 12 Using this system, 10 l of iopamidol (408 mg/ml) was delivered at a rate of 0.5 l/minute into the striatum. After completion of the infusion, the animals were observed daily for clinical deficits and were killed at the end of the observation period (3 days, three animals and 4 weeks, three animals). After the animals had been killed their brains were immediately removed and frozen at Ϫ70˚C. The brains were later cut coronally into 20-m-thick serial sections (throughout the entire brain) on a cryostat at Ϫ18 to Ϫ20˚C and stained with H & E, Luxol fast blue, and Nissl.
Infusion of Iopamidol in Primates
Surgery. Applying the CED technique, iopamidol was delivered to various regions of the cerebral hemispheric white matter of four adult nonhuman primates (Macaca mulatta) ( Table 1) . After induction of sedation, the animals underwent endotracheal intubation and induction of general anesthesia with inhaled halothane (1-4%). Each primate's temperature, heart rate, oxygen saturation, electrocardiographic signals, and end-tidal PCO 2 were monitored. The head of each animal was secured in a stereotactic frame (Kopf Instruments). Using a sterile technique, a midline scalp incision was made from the anterior to the posterior aspect of the vertex, and self-retaining retractors were used to expose the underlying skull. One or two 1-cm burr holes were made over the stereotactically determined entry point(s) and the underlying dura mater was incised. A silicate infusion cannula (Plastics One, Inc., Roanoke, VA; outer diameter 0.36 mm, inner diameter 0.15 mm) was stereotactically placed through the dural opening and positioned with its tip at the predetermined target. The silicate infusion cannula was connected to the vinyl tubing (Plastics One, Inc.; outer diameter 1.3 mm, inner diameter 0.6 mm) via a side port and secured to the skull with methylmethacrylate. The vinyl tubing was then tunneled subcutaneously under the scalp and posterior nuchal skin, and exited through the skin between the scapula in the midline. A 3-ml syringe containing the infusate was connected to the vinyl tubing and placed in a microinfusion pump (MiniMed Technologies, Sylmar, CA). The pump was secured in a custom-made jacket (Lomir Biomedical, Inc., Malone, NY). A separate additional cannula, vinyl subcutaneous tubing, and pump were placed in a similar manner in animals in which two infusions were performed (Table 1) . After the infusion apparatus had been placed, the wound was closed and the animal was brought to the imaging center and secured to the CT scanner.
Real-Time CT Scanning. Coronal CT scans were obtained to determine the precise location of the cannula(e) before any infusion was initiated. Once the cannula position had been confirmed, the infusions had been started, and real-time coronal (slice thickness 1 mm, 1-mm spacing) CT scans were obtained at 15-to 60-minute intervals while the animal lay prone. In all instances the initial rate of infusion was 0.5 l/minute; this rate was maintained for 30 to 60 minutes and then increased to 1 to 3.5 l/minute. The CT scans were analyzed on a Sun Workstation (Sun Microsystems, Inc., Palo Alto, CA). The V d was calculated using a threshold for segmentation consisting of 10% of the value obtained from the region of interest containing the maximal optical density. To determine the homogeneity of infusion over the infused V d , line profiles were obtained through the center of the infusion as seen on coronal images.
Postinfusion CT Scanning. One primate underwent daily CT scanning starting on postinfusion Day 1 and continuing until Day 5. Coronal (slice thickness 1 mm, 1-mm spacing) CT scans were obtained while the animal lay prone.
Clinical Evaluation. With the exception of the primate used for the QAR analysis, which was killed immediately after infusion completion, the animals were observed daily for medical problems or neurological deficits during the study (Յ 5 months). Three surviving primates were also observed by performing postoperative videotaping.
Quantitative Autoradiography Analysis. Quantititative autoradiography is a highly accurate method of determining spatial distributions of radiolabeled molecules within tissue. Radioisotope emissions from infused tissue sections release energy onto a superimposed photographic film, forming density images that can be quantified. To determine precisely the spatial distribution of LMW and HMW radiolabeled compounds and to determine the accuracy of iopamidol as a surrogate tracer for these variously sized compounds, we performed QAR on tissue sections obtained from a primate that underwent bilateral coinfusions of iopamidol (concentration 408 mg/ ml) with range of radioactivity was 400 to 800 nCi/g of brain. The animal was killed immediately after completion of the infusion, and the brain was harvested and sectioned as described later. Twenty-micrometer-thick sections and 14 C standards (range 0.002-35 Ci/g; American Radiolabeled Chemicals, Inc., St. Louis, MO) were exposed on BAS-MS imaging plates (Fuji Medical Systems, Stamford, CT), and developed using a BAS-5000 Bio-Imaging Analyzer (Fuji Medical Systems). The area of distribution on each slide was measured with the aid of the Image Gauge (version 3.45) software program (Fuji Medical Systems). A threshold for segmentation of 10% of the value obtained from the region of interest containing the maximal optical density was used to determine the area of distribution. The V d was calculated by summing the areas and multiplying this sum by 0.1 mm. To determine the homogeneity of infusion over the infused V d , line profiles were obtained through the center of the infusion, as determined using autoradiography.
Histological Analysis. The animals were killed by an intravenous overdose of pentobarbital (90 mg/kg) at the completion of the observation period (Table 1 ). All animals were perfused with phosphate-buffered saline followed by 4% paraformaldehyde. Their brains were immediately removed and frozen at Ϫ70˚C. Twentymicrometer-thick coronal sections throughout the brain were cut on a cryostat at Ϫ18 to Ϫ20˚C. The sections were stained using H & E, Luxol fast blue, and Nissl.
Statistical Analysis. Statistical analysis was performed using commercially available software. Specific statistical tests were used as defined elsewhere in the text.
Results
Rat Toxicity Studies
None of the six rodents in which the CED technique was used to deliver iopamidol (10 l) to the right striatum had clinical evidence of toxicity during a short-term (3 days, three animals) or long-term (4 weeks, three animals) observation. A histological analysis of tissues excised from these six animals revealed normal tissue architecture with minimal gliosis (25-m radius) that was limited to the region immediately surrounding the cannula tract.
Primate Infusion Studies
Real-Time CT Scanning. Computerized tomography scanning performed at 15-to 60-minute intervals throughout the infusions revealed that the anatomical region infused with iopamidol was clearly distinguishable from the surrounding noninfused tissue (Fig. 1) . The region surrounding the cannula tip steadily filled with contrast material, with an increasing V i (Fig. 1) .
Volumetric analysis of the infused region at various time points throughout the infusion revealed that the V d increased linearly (r 2 = 0.97) with the increasing V i ( across the infused region formed a square-shaped distribution pattern with a relatively steep dropoff of concentration at the edges (Fig. 3) .
Postinfusion CT Scanning. Postinfusion scanning performed in one animal (Primate 1) daily up to 5 days after completing the infusion revealed an increase in the V d on postinfusion Day 1. A quantitative assessment of the increase was limited by the reduction in imaging intensity of the portion of the V d that was below the segmentation threshold. This reduction remained stable until the density of the region perfused by iopamidol reached the density of surrounding tissue by postinfusion Day 3 (Fig. 4) . Crosssectional line profiles performed through the infused region on postinfusion Day 1 revealed a flattening of the concentration distribution pattern and a loss of the square-shaped profile that was observed on CT scans during the infusion (Fig. 3) .
Clinical Evaluation. Serial clinical examinations of three primates after infusion showed no evidence of toxicity for the duration of observation, which lasted up to 5 months (Table 1) . One animal (Primate 2) was killed immediately after infusion so that we could perform a tissue QAR analysis.
Quantitative Autoradiography Analysis. Imaging and the QAR tissue analysis (Primate 2) of the coinfusion of iopamidol and either Table 2 ). The QAR patterns and regions of distribution for the labeled sucrose and dextran matched those observed on the CT scans (Fig. 5) . The V d s obtained in Primate 2 by imaging were lower than the V d s measured by QAR-19.7% lower for sucrose and 7.5% lower for dextran-but the differences were not significant, given an estimated coefficient of variation of 0.17 for the V d derived from CT scanning and a similar value for the V d derived from QAR (Table 2 ). Similar to the CT analysis of homogeneity, cross-sectional line profiles across the infused region on QAR formed a squareshaped distribution pattern with a steep dropoff of concentration at the edges (Fig. 6) .
Histological Analysis. A gross examination of the brain revealed normal weight and no evidence of edema. Sections throughout the region of infusion prepared using Luxol fast blue, H & E, and Nissl stains revealed a normal tissue architecture. Gliosis was limited to the region immediately surrounding the cannula track (within a 50-m radius). Table 1 ). The V d of iopamidol was determined using CT scanning, and the V d s of the individual agents was determined using QAR. 
Discussion
Convection-Enhanced Delivery
Convection-enhanced delivery relies on bulk flow that is driven by a small pressure gradient to distribute molecules within the interstitial spaces of the CNS. Unlike intraventricular, intrathecal, or polymer implant delivery techniques, which rely on diffusion, convection is not limited by the infusate's molecular weight, concentration, or diffusivity. 1, 6, 15, 17, 20, 23 Moreover, because convective delivery directly distributes molecules within the parenchyma, it can be used to target selected regions of the CNS in a manner that bypasses the blood-nervous system barrier, which limits the distribution and efficacy of systemically delivered agents. 20 The properties of convective delivery permit the homogeneous distribution of small and large molecules over clinically relevant volumes in a safe and reproducible manner within peripheral nerves, the spinal cord, the brainstem, and the brain. 1, 4, 10, [12] [13] [14] 16, 18, 21, 22 Previously, we examined the feasibility, properties, and safety of convective distribution of HMW surrogate imaging tracers for magnetic resonance and CT imaging. 13, 18 These studies showed that albumin labeled with Gd (for magnetic resonance imaging) or iopanoic acid (for CT scanning) could be used to monitor accurately the convective delivery of a large protein ( 14 C-albumin; MW 72 kD). Because both these tracers are of HMW and are not significantly affected by diffusive forces, they may not accurately track LMW substances, particularly during long infusions during which diffusion can influence distribution at the leading edges of the V d . Here an LMW, commercially available tracer suitable for CT scanning was examined using in vivo real-time monitoring, and the distribution of the tracer was compared with the distribution of small and large molecules within the primate brain.
Current Study
Iopamidol. Iopamidol is a nonionic, organic, iodine-based contrast agent suitable for use in CT scanning. It was chosen as an imaging surrogate tracer for CED for several reasons. Because iopamidol contains organically bound iodine, it can be easily and reliably imaged during CT scanning. It has been used extensively for CT scanning, particularly myelography, and its safety when used in the CNS has been well-documented, even in patients who previously have displayed intolerance to iodine derivatives. 5 Because iopamidol has a low octanol-water coefficient (logP value Ϫ2.42), its transfer across the blood-brain barrier into the vascular compartment is minimal. This property should allow its distribution during CED to approximate closely the convective distribution of therapeutic agents that do not cross the blood-nervous system barrier, a feature of the most suitable agents for CED in the CNS.
Real-Time Imaging Characteristics. Computerized tomography scanning during iopamidol infusion revealed a welldefined V d that was easily distinguished from the surrounding brain parenchyma. The region surrounding the tip of the cannula was filled steadily with an increasing V i (Fig. 1) . During infusion into the centrum semiovale, tracer distribution was confined to the white matter, reflecting the preferential flow of the agent and the reduced resistance to the flow of fluid along the longitudinal axes of white matter tracts, relative to gray matter. This, in turn, was reflected as a greater or lesser anisotropy, depending on the local degree of alignment of fiber tracts. By taking advantage of the low resistance to fluid flow in white matter, perfusion of large regions of the cerebral hemisphere was possible. Although clinically significant volumes of the brain were perfused with infusate in this study, no attempt was made to perfuse larger brain volumes. Thus, the maximum volume of brain perfusion was not determined and could be much greater than the volumes achieved, because of the continued linear increase in the V d associated with the increasing V i (Fig. 2) .
Postinfusion Imaging Characteristics. Twenty-four hours after completion of the infusion CT scanning revealed expansion of the V d , but no further expansion was detected on subsequent imaging (Days 2-5). This behavior is consistent with the diffusional and continued convective spread of iopamidol after the end of infusion (Fig. 4) . Because of the ongoing local clearance of iopamidol, the maximal diffusional spread could not be detected, producing an apparent stabilization of the estimated volume of distribution at later observation times (postinfusion Day 2; Fig. 4 ). Because diffusion and continued convection drive the distribution of an LMW tracer (such as iopamidol) after completion of infusion, the use of imaging to determine the accurate distribution of some LMW molecules may be less accurate at distant time points.
Homogeneity. The distribution of the tracer during infusion was relatively homogeneous in the targeted white matter. An analysis of infusate density on CT scans (Fig. 3) and QAR images (Fig. 6 ) revealed uniformity and a sharp dropoff at the edges of the infused region during and immediately after infusion. This square-shaped concentration profile was maintained throughout the period of infusion. These findings are consistent with the bulk-flow properties of CED and the results of a number of previous studies in which convective delivery was used to transport macromolecules (including 14 C-albumin) to the CNS. 12, 18 Nevertheless, as expected and consistent with diffusional spread at the perfusion margins after completing infusion, crosssectional line profiles made through the infused region on postinfusion images (postinfusion Days 1-5) revealed flattening of the concentration distribution pattern and a loss of the square-shaped profile that was observed on real-time CT scanning during infusion (Fig. 3) . Despite this flattening on postinfusion images, relatively homogeneous therapeutic levels (that is, levels higher than a desired threshold concentration) of an infused agent could be maintained at distant time points in a targeted region (that is, tissue perfused during convective infusion).
Reliability as a Surrogate Tracer. Iopamidol (777 D) is a reliable surrogate tracer for tracking the V d during CED of both small (sucrose, 359 D) and large (dextran, 70 kD) molecules characterized by a negligible metabolism and a low microvascular permeation during V i s of approximately 100 l over infusion times lasting approximately 2 hours. During infusion of a mixture of iopamidol with either sucrose or dextran, the V d of iopamidol, measured using CT scanning, closely approximated the V d s of both compounds as determined using QAR: the differences were only 19.7 and 7.5%, respectively (Table 2) , which correspond to small differences in equivalent spherical radii (difference of 0.3 mm for sucrose and 0.1 mm for dextran). Because the coefficient of variation of V d for both CT scanning (Table 1) and QAR, given typical radial errors of 7%, is approximately 17%, these differences are not statistically significant. The anatomical location and pattern of distribution of infusate, as determined using CT scanning, corresponded closely with the location and pattern as determined using QAR (Fig. 5) .
A critical issue for practical application of these findings is the determination of the range of CED conditions under which iopamidol will accurately trace the spread of the solute and identify when it begins to fail in its role. The use of iopamidol in tracking macromolecular distribution (for example, dextran [MW 70 kD]) is particularly subject to difficulty because the lower molecular weight of iopamidol enhances its spread by diffusional transport and its clearance by microvascular efflux (despite its high hydrophilicity). To quantify this sensitivity, a mathematical model of CED was used to estimate the difference in V d between iopamidol and dextran over a wide range of combinations of infusion rates (q v s) and V i s. These differences were used to estimate the percentage of error in the use of iopamidol to estimate the V d of dextran.
The CED model was formulated to the first order as an isotropic convection-diffusion-reaction differential mass balance over the infused solute concentration c, coupled with an inner boundary condition that equates the infusate concentration to the interstitial concentration (that is, c inf = c ()/ where is the catheter radius and is the extracellular volume fraction) and an outer boundary condition of zero solute concentration. Spherical symmetry was adopted both for simplicity and because it forces the fluid velocity to decrease rapidly with distance from the catheter tip (for isotropic media, a maximal decrease occurs in this geometry), thereby causing the convective-to-diffusion transition (primarily that of iopamidol) to occur as close to the tip as possible. This tends to reduce to core estimates the V d s at which iopamidol and dextran begin to diverge due to molecular transport differences. Anisotropy was neglected for these agents because it accounts primarily for the shape of the V ) is the rate constant used to describe the solute efflux due to microvascular transport (equal to the permeability area product divided by the extracellular volume fraction, ps/ 17 ). Explicit treatment of osmotic shifts is neglected because the experimental V d /V i ratios of iopamidol solutions are identical to previous results in studies involving isotonic infusates. 4 Radial concentration profiles for iopamidol and dextran were then computed from the CED model for a wide range of infusion conditions defined by pairings of infusion rates and volumes (with 0.1 Յ q v Յ 1.4 l/minute and 25 Յ V i Յ 1200 l). For each simulation, the V d was computed from the radial value corresponding to the point at which the concentration of agent in the extracellular fluid decreased to 15% of its infusate value (that is, the 15% threshold). 
These values were used to determine a q v -V i -locus along which the error was maintained at a fixed percentage. These loci appear in Fig. 7 for the error percentages of 20, 25, and 50%. Thus, the region in Fig. 7 below a given percentage locus corresponds to the set of infusion conditions in which the absolute error in the estimate of the V d of dextran using iopamidol is less than this percentage. As noted previously, typical experimental errors in the determination of the V d of iopamidol alone are approximately 20%. Hence all infusion rate-infusion volume (q v -V i ) combinations below the 20% line correspond to delivery situations in which errors stemming from iopamidol's use as a surrogate for a nonreactive macromolecule do not exceed the uncertainty of the measurement itself. Thus, these q v -V i combinations are useful for tracking nonreactive compounds using CT scanning with iopamidol, with the caveat that the chosen infusion rate must not be so high that an unacceptable backflow along the catheter is encountered. For this reason, infusion rates are often limited to Յ 0.5 l/minute for gray matter and Յ 1 l/minute for white matter. 16 For q v -V i combinations above the 20% line (for example, a larger V i and/ or slower infusion rates), diffusion becomes the dominant force for LMW iopamidol distribution and, as a result, it will no longer have a similar transport behavior (that is, convection) as an HMW molecule such as dextran.
When iopamidol is used to track reactive molecules (in contrast to molecules that are nonreactive and extracellularly localized, such as sucrose and dextran), the same set of q v -V i combinations identified earlier may be used. In this case, however, the iopamidol distributions indicate only the boundary of potential tissue penetration because the most reactive compounds would have cleared from the extracellular space well before reaching this boundary. Thus, the boundary of iopamidol serves not only to identify the maximum distribution of the pharmacological response in the target region, but also whether sensitive nontargeted regions are likely to lie outside the distribution range of a given drug delivery protocol. Safety. Convective distribution of iopamidol was well tolerated and without evidence of a neurological deficit or gross and histopathological evidence of toxicity in rodent and primate models. Although iopamidol is a relatively inert substance, additional studies may be necessary to determine if an adverse interaction between it and a coinfused therapeutic compound could occur.
Potential Uses of Surrogate Tracers in CED
The potential of using CED combined with a surrogate tracer not only to effectively distribute therapeutic molecules to the brain but also to monitor the distribution of infusate noninvasively in real time (including the pattern of distribution, the V d , and the anatomical location of the infusate) should prove critical for ensuring that the proper distribution of a therapeutic agent needed for maximum efficacy has been achieved. Ideally, the therapeutic compound and the coinfused tracer would have similar physical and biochemical properties (for example, receptor binding, cellular uptake, metabolic clearance, and the octanol-water coefficient), so that the distribution of the therapeutic compound could be precisely determined using CT scanning. Consequently, very small (MW Ͻ 600 D), reactive, or highly lipophilic compounds, which are not well suited for CED because of rapid efflux across the microvasculature, may not be accurately monitored using this method, unless they are tagged directly with an imaging marker.
Based on the foregoing discussion, as a surrogate tracer certain limitations in the use of iopamidol must be recognized. During CED in the CNS the extracellular fluid of the tissue is being displaced at a rate that depends on the rate of infusion. As long as the displacement of extracellular fluid at the margin of the perfused region is moving radially from the point of infusion at a rate that is faster than the rate of diffusion, distribution by convection will dominate (for drugs with limited degradation in the extracellular fluid, limited binding by the tissue, limited permeation across the vessels and into the circulation, and limited cellular uptake) and produce a distinct boundary of distribution with a sharp drop in concentration at the perfusion boundary during and immediately after infusion. After the infusion is terminated, however, diffusion and convection continue, albeit at a slower pace, and the slope of the concentration at the margin of perfusion becomes less steep. Note that in Fig. 7 the maximum infusion volume at which the accuracy of iopamidol for predicting the distribution of an inert drug such as sucrose or dextran has an error no greater than 20% is 800 l with the peak infusion rate of 1.4 l/minute; with a V d /V i ratio of 5:1 the corresponding volume of tissue perfused at this combination of infusion rate and volume is 4 ml. Whether the maximum rate of infusion in humans without backflow along the catheter track will be 1.4 l/minute has not yet been established and whether the maximal infusion rates in white matter will be comparable remains to be learned; however, even if the maximal infusion rates without backflow in these settings prove to be several-fold greater than 1.4 l/minute, the V d for which iopamidol will accurately reflect the V d of the therapeutic drug will be limited to structures of only a few milliliters in volume. Furthermore, that is the case only for drugs with features of a relatively inert drug, such as described earlier. Thus, iopamidol should be useful for monitoring the distribution of certain LMW drugs in targeted regions of a relatively small volume, regions that might be targets for the treatment of pain, Parkinson disease, tremor, a well-defined epileptic focus, and so forth; but not for disorders requiring higher distribution volumes, such as gliomas and enzymatic storage disorders. Furthermore, the distribution of small, reactive, or lipophilic compounds that do not have features suited to CED may not be accurately monitored by the distribution of iopamidol, even for small volumes.
Conclusions
Real-time in vivo CT scanning of CED in which iopamidol is used as an imaging tracer appears to be safe, feasible, and should be suitable for monitoring the delivery of various LMW and HMW drugs under defined conditions. The application of these findings should enhance the development of novel treatments involving convective delivery of a variety of therapeutic agents.
